Doxepin binds with high specificity and affinity to the
histamine H(1) receptor compared with other receptors. Therefore, at low doses,
doxepin selectively antagonises H(1) receptors, which is believed to promote the initiation and maintenance of sleep. In three large, well designed, phase III trials in adult or elderly patients with chronic
primary insomnia, oral, low-dose
doxepin 3 or 6 mg once daily improved wake time after sleep onset, total sleep time and sleep efficiency to a significantly greater extent than placebo. Significant between-group differences in polysomnographic sleep recordings that favoured low-dose
doxepin were evident after a single administration of the
drug. Other efficacy measures, including patient-reported sleep quality, also favoured low-dose
doxepin over placebo. Symptom control was maintained for up to 12 weeks of low-dose
doxepin administration and there was no evidence of physical dependence or worsening
insomnia after
doxepin withdrawal. Oral, low-dose
doxepin 6 mg was also significantly more effective than placebo in a large, well designed trial modelling
transient insomnia in healthy adults, according to polysomnographic recordings (e.g. in latency to persistent sleep). Oral, low-dose
doxepin was generally well tolerated in clinical trials.